ATE465411T1 - Verfahren zur bestimmung von anfälligkeit einer person zur infektion - Google Patents

Verfahren zur bestimmung von anfälligkeit einer person zur infektion

Info

Publication number
ATE465411T1
ATE465411T1 AT03773640T AT03773640T ATE465411T1 AT E465411 T1 ATE465411 T1 AT E465411T1 AT 03773640 T AT03773640 T AT 03773640T AT 03773640 T AT03773640 T AT 03773640T AT E465411 T1 ATE465411 T1 AT E465411T1
Authority
AT
Austria
Prior art keywords
infection
determining
subject
suspension
person
Prior art date
Application number
AT03773640T
Other languages
English (en)
Inventor
Hans Boman
Mats Andersson
Katrin Puetsep
Goeran Carlsson
Original Assignee
Mabtech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mabtech Ab filed Critical Mabtech Ab
Application granted granted Critical
Publication of ATE465411T1 publication Critical patent/ATE465411T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03773640T 2002-10-10 2003-10-10 Verfahren zur bestimmung von anfälligkeit einer person zur infektion ATE465411T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0223655.2A GB0223655D0 (en) 2002-10-10 2002-10-10 Method of diagnosis
PCT/EP2003/011240 WO2004034061A2 (en) 2002-10-10 2003-10-10 Method for determining the susceptibility of a subject to infection

Publications (1)

Publication Number Publication Date
ATE465411T1 true ATE465411T1 (de) 2010-05-15

Family

ID=9945734

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03773640T ATE465411T1 (de) 2002-10-10 2003-10-10 Verfahren zur bestimmung von anfälligkeit einer person zur infektion

Country Status (9)

Country Link
US (1) US7591997B2 (de)
EP (1) EP1549957B1 (de)
JP (1) JP4874545B2 (de)
AT (1) ATE465411T1 (de)
AU (1) AU2003282027B2 (de)
CA (1) CA2501926A1 (de)
DE (1) DE60332257D1 (de)
GB (1) GB0223655D0 (de)
WO (1) WO2004034061A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0300207D0 (sv) 2003-01-29 2003-01-29 Karolinska Innovations Ab New use and composition
US20100292132A1 (en) * 2007-09-11 2010-11-18 Dorian Bevec Use of insulin c-peptide, alone or in combination with glp-1, as a therapeutic agent
EP2188015A2 (de) * 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Verwendung von salusin beta allein oder in kombination mit octreotid als therapeutisches mittel
US20190300575A1 (en) * 2018-03-29 2019-10-03 Deetex, LLC Lytic peptide biosensor and methods of making and using the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159936A (en) 1993-07-20 2000-12-12 The Regents Of The University Of California Compositions and methods for treating and preventing microbial and viral infections
US5972594A (en) * 1997-02-05 1999-10-26 University Of Pittsburgh Method for screening for reproductive tract inflammation and preeclampsia using neutrophil defensins
FR2767832B1 (fr) * 1997-08-29 2001-08-10 Genset Sa Polypeptide defensine humaine def-x, adn genomique et adnc, composition les contenant et applications au diagnostic et au traitement therapeutique
WO1999013080A1 (en) 1997-09-10 1999-03-18 Zymogenetics, Inc. Beta-defensins
JP2001288105A (ja) * 2000-04-05 2001-10-16 Yoshihiro Abiko 歯周炎用医薬
DE10028725B4 (de) * 2000-06-09 2013-03-21 Jürgen Bux Primärstruktur des HNA-2a (ehemals NB1)-Antigens
EP1301797A2 (de) * 2000-07-17 2003-04-16 Hansa Medical AB Antimikrobielles mittel
WO2002013857A2 (en) * 2000-08-17 2002-02-21 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
US20020072495A1 (en) 2000-09-21 2002-06-13 Oleg Chertov LL-37 is an immunostimulant
AU2002240137A1 (en) * 2001-01-30 2002-08-12 University Of Iowa Research Foundation Antiviral activities of primate theta defensins and mammalian cathelicidins
US20030175755A1 (en) * 2002-03-05 2003-09-18 Yoshihiro Abiko Method of collecting data for estimation of susceptibility to periodontal disease

Also Published As

Publication number Publication date
JP2006502395A (ja) 2006-01-19
US20070059691A1 (en) 2007-03-15
AU2003282027A1 (en) 2004-05-04
GB0223655D0 (en) 2002-11-20
WO2004034061A2 (en) 2004-04-22
AU2003282027B2 (en) 2010-05-13
US7591997B2 (en) 2009-09-22
CA2501926A1 (en) 2004-04-22
DE60332257D1 (de) 2010-06-02
EP1549957A2 (de) 2005-07-06
WO2004034061A3 (en) 2004-05-21
JP4874545B2 (ja) 2012-02-15
EP1549957B1 (de) 2010-04-21

Similar Documents

Publication Publication Date Title
ATE532070T1 (de) Entzündungsmarker zum nachweis und zur prävention von diabetes mellitus
DE60025233D1 (de) Verfahren zur beruhigen von menschen unter verwendung von körperpflegemitteln
EA200600452A1 (ru) Автоматизированные способы и системы для обнаружения и анализа сосудистых бляшек
DE60319426D1 (de) Verfahren zur bestimmung von azimut- undhöhenwinkeln durch verwendung eines einachsen-richtungfindungssystems
DE69422687D1 (de) Biosensor zur hämatokritbestimmung
DE60138829D1 (de) Verfahren zur unterscheidung des reizkolons von der entzündlichen darmerkrankung (inflammatory bowel disease, ibd) und zur überwachung von patienten mit ibd unter verwendung von endogenem gesamt-lactoferrin als marker
DE60023936D1 (de) Methoden zur verwendung von randomisierten zinkfingerprotein-bibliotheken zur identifizierung von genfunktionen
DE3882058D1 (de) Immunoreaktives reagens, verfahren zu seiner herstellung und seine verwendung zur bestimmung einer immunoreaktiven spezies.
ATE127853T1 (de) Verfahren zur bestimmung der funktionellen wirkung von freiem protein s oder protein c in einer plasmaprobe.
DE59009072D1 (de) Verfahren und vorrichtung zur ermittlung von chemischen zuständen von lebendem, tierischem oder menschlichem gewebe unter verwendung von magnetischer resonanz.
ATE532073T1 (de) Verfahren zur identifizierung einer untersuchungsperson in gefahr, an herzversagen zu erkranken, durch bestimmung des galectin-3- oder thrombospondin-2-spiegels
DE69105978D1 (de) Verfahren zur verminderung von störungen in einer fluoreszenzbestimmung.
DE69833660D1 (de) Nukleinsäuresonden zur detektion von candida-spezies
ATE465411T1 (de) Verfahren zur bestimmung von anfälligkeit einer person zur infektion
DE69204157D1 (de) Verfahren zur bestimmung von anti-rns-antikörpern.
DE69937678D1 (de) Verfahren zur schnellen bestimmung von bakterien
DE69625581D1 (de) Cyanidfreies Reagenz und Verfahren zur Bestimmung von Hämoglobin und Leukozytendifferenzierung
DE60301283D1 (de) Verfahren zur Bestimmung von Biopolymeren
DE69934789D1 (de) Verfahren zur bestimmung der antibiotikasensitivität von bakterien
DE50115503D1 (de) Verfahren und mittel zur bestimmung von gesamthärte
DE59101035D1 (de) Verfahren zur bestimmung von gaskonzentrationen und gassensor mit festem elektrolyten.
ATE153770T1 (de) Künstliche standard- und kontrollseren zur verwendung in verfahren zur bestimmung von antikörpern
DE59305225D1 (de) Verfahren zur Bestimmung von Thrombose verursachenden Lupus-anticoagulant-Antikörpern
DE69917336D1 (de) System und verfahren zur bestimmung von minimum- und maximumwerten unter verwendung von letzt-ereignis- und gleitfenstertechniken
ATE384266T1 (de) Verfahren zur prognose des kumulativen überlebens von patienten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties